


# Circulating trimethylamine *N*-oxide levels do not predict 10-year survival in patients with or without coronary heart disease

■ Espen Ø. Bjørnstad<sup>1</sup> , Indu Dhar<sup>2</sup>, Gard F. T. Svingen<sup>3</sup>, Eva R. Pedersen<sup>3,4</sup>, Stein Ørn<sup>1</sup>, Mads M. Svenningsson<sup>3</sup>, Grethe S. Tell<sup>5</sup>, Per M. Ueland<sup>4</sup>, Gerhard Sulo<sup>6</sup>, Reijo Laaksonen<sup>7</sup> & Ottar Nygård<sup>3,4</sup>

From the <sup>1</sup>Department of Cardiology, Stavanger University Hospital, Stavanger, Norway; <sup>2</sup>Mohn Nutrition Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway; <sup>3</sup>Department of Cardiology, Haukeland University Hospital, Bergen, Norway; <sup>4</sup>Department of Clinical Science, University of Bergen, Bergen, Norway; <sup>5</sup>Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; <sup>6</sup>Centre for Disease Burden, Norwegian Institute of Public Health, Bergen, Norway; and <sup>7</sup>Finnish Cardiovascular Research Center, University of Tampere, Tampere, Finland

**Abstract.** Bjørnstad EØ, Dhar I, Svingen GFT, Pedersen ER, Ørn S, Svenningsson MM, et al. Circulating trimethylamine *N*-oxide levels do not predict 10-year survival in patients with or without coronary heart disease. *J Intern Med.* 2022;**292**:915–924.

**Background.** Trimethylamine *N*-oxide (TMAO) is an amine oxide generated by gut microbial metabolism. TMAO may contribute to atherothrombosis and systemic inflammation. However, the prognostic value of circulating TMAO for risk stratification is uncertain.

**Methods.** We assessed prospective relationships of plasma TMAO with long-term risk of all-cause, cardiovascular (CV), and non-CV mortality in the Western Norway Coronary Angiography Cohort (WECAC; 4132 patients with suspected coronary artery disease) and the Hordaland Health Study (HUSK; 6393 community-based subjects). Risk associations were examined using Cox regression analyses.

**Results.** Mean follow-up was 9.8 and 10.5 years in WECAC and HUSK, respectively. Following adjust-

ments for established CV risk factors and indices of renal function in WECAC, the hazard ratios (HRs) (95% confidence intervals [CIs]) per one standard deviation increase in log-transformed plasma TMAO were 1.04 (0.97–1.12), 1.06 (0.95–1.18), and 1.03 (0.93–1.13) for all-cause, CV, and non-CV mortality, respectively. Essentially similar results were obtained in patients with angiographically significant coronary artery disease and patients with reduced left ventricular ejection fraction. Corresponding HRs (95% CIs) in the HUSK cohort were 1.03 (0.96–1.10), 1.01 (0.89–1.13), and 1.03 (0.95–1.12) for all-cause-, CV, and non-CV mortality, respectively.

**Conclusions.** Circulating TMAO did not predict long-term all-cause, CV, or non-CV mortality in patients with coronary heart disease or in community-based adults. This large study does not support a role of TMAO for patient risk stratification in primary or secondary prevention.

**Keywords:** cardiovascular risk factors, coronary artery disease, mortality, prevention, trimethylamine *N*-oxide

## Introduction

Circulating gut microbiota-derived metabolites are increasingly recognized as markers of disease progression and prognosis [1]. The amine oxide, trimethylamine *N*-oxide (TMAO), has received par-

ticular interest as a potential mediator of cardiovascular (CV) and metabolic disorders [2, 3]. TMAO is produced by hepatic oxidation of trimethylamine, which is generated by gut microbial metabolism of compounds like choline, phosphatidylcholine, and carnitine. Large amounts of

free TMAO can also be obtained from seafood sources. TMAO elimination is almost exclusively by renal excretion [4]. Thus, diet, gut microbial composition, and kidney function are important determinants of plasma TMAO levels [5], which show considerable intra-individual variation [6].

Limited data from mechanistic and animal studies suggest pro-atherothrombotic and pro-inflammatory properties of TMAO [1]. Accordingly, recent meta-analyses of high-risk patient cohorts reported dose-dependent associations of baseline TMAO with CV outcomes [7, 8]. However, important inconsistencies exist across observational studies, and the clinical value of circulating TMAO in patient risk stratification is uncertain [5]. Also, data on TMAO and outcomes in the general population are scarce [9].

In the present study, we examined prospective associations of plasma TMAO with long-term risk of all-cause, CV, and non-CV mortality in two large separate cohorts of subjects with different baseline risk: a secondary prevention cohort of patients with suspected chronic coronary syndrome and a primary prevention cohort of community-dwelling adults.

## Materials and methods

### *Study cohorts*

Two prospective cohort studies from Western Norway were included. The Western Norway Coronary Angiography Cohort (WECAC) enrolled 4164 patients who underwent elective invasive coronary angiography due to suspected chronic coronary syndrome during 2000–2004 [10]. A total of 61.8% ( $n = 2573$ ) of the patients were additionally included in the Western Norway B-vitamin Intervention Trial (clinicaltrials.gov:NCT00354081) [11].

The Hordaland Health Study (HUSK) recruited 7051 community-dwelling adults born during 1925–1927 or 1950–1951, and has been extensively described in previous reports [12]. Baseline examinations were conducted during 1997–1999 (<https://husk-en.w.uib.no/>).

Written informed consent was provided by all study subjects. Both study protocols were approved by the Norwegian Data Inspectorate and by

the Regional Committee for Medical and Health Research Ethics.

Patients without data on plasma TMAO or covariates included in the multivariable risk models were excluded, leaving 4132 participants in WECAC and 6393 subjects in HUSK for the final analyses.

### *Baseline data and biochemical analyses*

Previous reports have described the collection of clinical and biochemical data, including the handling and storage of blood samples [10, 13]. Smoking status was defined according to self-reports and/or plasma cotinine concentrations  $\geq 85$  nmol/L. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula [14]. In WECAC, angiographically significant coronary artery disease (CAD) was defined by the presence of a lesion with  $\geq 50\%$  stenosis in any main coronary artery (i.e., the left anterior descending artery, the right coronary artery, or the circumflex artery), including their major side branches [15]. Left ventricular ejection fraction (LVEF) was determined by echocardiography or ventriculography.

Plasma TMAO was analyzed by BEVITAL AS ([www.bevital.no](http://www.bevital.no)) using liquid chromatography–tandem mass spectrometry (LC-MS/MS) [16]. Participants of HUSK and the majority (68.5%) of subjects in WECAC were nonfasting (patients reporting  $>6$  h since their last meal were considered fasting).

### *Study endpoints and follow-up*

The endpoints were all-cause, CV, and non-CV mortality. CV mortality was classified according to the 10<sup>th</sup> Revision of the International Classification of Diseases (codes I00–I99 or R96). Endpoint data were obtained from the Norwegian Cause of Death Registry, using each participant's unique 11-digit personal identification number. The Norwegian Cause of Death Registry covers more than 98% of the Norwegian population [17]. Study subjects were followed until death or through 2012.

### *Statistical analyses*

Continuous variables were reported as means (standard deviations [SDs]) and categorical variables as percentages. Baseline concentrations of TMAO were additionally reported as medians (interquartile ranges [IQRs]). Differences in base-

line characteristics across TMAO quartiles were assessed using linear regression for continuous variables and logistic regression for categorical variables.

Univariate, age-, and sex-adjusted (Model 1) and multivariable (Model 2) Cox regression models were used to obtain hazard ratios (HRs) and corresponding 95% confidence intervals. HRs are reported per one SD increment of log-transformed plasma TMAO and across TMAO quartiles. Model 2 was adjusted for age (continuous), sex (binary), hypertension (binary), diabetes mellitus (binary), total cholesterol (continuous), smoking (binary), body mass index (continuous), and eGFR (continuous). Potential effect modifications according to variables in Model 2 and LVEF ( $\leq 40$  vs.  $>40\%$ ) were assessed by adding interaction terms to Model 2. In WECAC, we additionally performed a sensitivity analysis restricted to patients with angiographically significant CAD at baseline.

We used the statistical package SPSS (version 27; SPSS IBM). Reported probability values were two-tailed, and a  $p < 0.05$  was considered statistically significant. Subgroup analyses were considered exploratory and were reported without adjustments for multiple comparisons.

## Results

### Baseline characteristics

Baseline characteristics of the two study cohorts are presented in Table 1. Of the 4132 patients in WECAC, 71.9% were men, 46.6% had hypertension, and 31.7% were current smokers. The mean (SD) age at inclusion was 62 [10] years. A total of 3095 (74.9%) had angiographically significant CAD. Mean (SD) and median (IQR) TMAO concentrations were 9.03 (12.5) and 5.7 (3.6–9.7)  $\mu\text{mol/L}$ , respectively.

Of the 6393 HUSK participants, 44.5% were men, 18.1% had hypertension, and 25.4% were current smokers. Mean (SD) and median (IQR) TMAO concentrations were 9.1 (16.8) and 4.7 (3.1–8.3)  $\mu\text{mol/L}$ , respectively.

Across both cohorts, subjects with higher TMAO concentrations were more likely to have diabetes and hypertension, whereas a lower proportion were smokers. Plasma TMAO showed a negative association with eGFR and LVEF. Positive associations were observed with circulating TMAO precursors

such as choline, betaine, trimethyllysine, and gamma-butyrobetaine.

### TMAO and risk of mortality

The mean (SD) follow-up time was 9.8 (2.6) and 10.5 (1.9) years in WECAC and HUSK, respectively.

In WECAC, 905 (21.9%) patients died, 413 from CV and 492 from non-CV causes. In univariate analyses, TMAO was significantly associated with all endpoints. However, these risk relationships were fully attenuated after multivariable adjustments (Table 2). In Model 2, the HRs for all-cause, CV, and non-CV mortality per one-SD increment of log-transformed TMAO were 1.04 (0.97–1.12), 1.06 (0.95–1.18), and 1.03 (0.93–1.13), respectively (Table 2 and Fig. 1). The risk estimates did not differ according to the fasting status (data not shown).

In HUSK, a total of 884 subjects (13.8%) died, 287 from CV and 597 from non-CV causes. As in WECAC, TMAO was a strong predictor of mortality in univariate analyses. However, the associations did not persist in models adjusted for age and sex (Table 3). In multivariable adjusted analyses, the HR per one-SD increment of log-transformed TMAO was 1.03 (0.96–1.10) for all-cause mortality, with numerically similar results for CV and non-CV mortality (all  $p \geq 0.28$ ).

Analyses comparing the fourth versus first TMAO quartile or trends across quartiles yielded comparable results across both cohorts (Tables 2 and 3).

### Sensitivity and subgroup analyses

A sensitivity analysis restricted to patients with angiographically significant CAD in WECAC ( $n = 3095$ ) showed a similar null association between plasma TMAO and mortality (Table S1).

Subgroup analyses according to baseline characteristics are shown in Table S2. The risk estimates were generally consistent in subgroups, including sex, prevalent hypertension, and diabetes. Notably, across both cohorts, there was a more pronounced TMAO–mortality relationship in patients with lower eGFR. However, the differences were numerically small and not statistically significant in WECAC. There was no interaction according to baseline LVEF (available in WECAC only).

To examine the importance of eGFR as a potential confounder in WECAC, we additionally examined

**Table 1.** Baseline characteristics of patients with suspected coronary heart disease (WECAC) and community-based subjects (Hordaland Health Study cohort) according to quartiles of plasma trimethylamine N-oxide

WECAC (n = 4132)					
	Quartile 1 (<3.6)	Quartile 2 (3.6–5.7)	Quartile 3 (5.7–9.7)	Quartile 4 (>9.7)	<i>P</i> <sub>trend</sub>
Age, years	58 (11)	61 (10)	63 (10)	65 (10)	<0.001
Female sex, %	33.4	29.5	25.8	23.6	<0.001
BMI, kg/m <sup>2</sup>	26 (4)	26 (4)	26 (4)	26 (4)	0.61
Hypertension, %	39.6	44.9	46.8	55.3	<0.001
Diabetes mellitus, %	8.0	10.2	12.9	16.2	<0.001
Current smoking, %	35.5	33.9	31.0	26.3	<0.001
eGFR, ml/min per 1.73 m <sup>2</sup>	95 (13)	90 (14)	86 (16)	80 (20)	<0.001
Total cholesterol, mmol/L	5.1 (1.2)	5.1 (1.1)	5.1 (1.2)	5.0 (1.2)	0.06
LDL-C, mmol/L	3.1 (1.0)	3.1 (1.0)	3.1 (1.0)	3.1 (1.0)	0.33
HDL-C, mmol/L	1.3 (0.4)	1.3 (0.4)	1.3 (0.4)	1.3 (0.4)	0.14
Left ventricular ejection fraction, %	65 (10)	64 (11)	63 (12)	63 (12)	<0.001
CRP, mg/L	3.6 (6.9)	3.8 (7.4)	3.7 (7.5)	3.7 (7.0)	0.78
Extent of CAD, %					<0.001
No stenotic vessels	29.9	25.7	23.7	21.0	
One-vessel disease	24.4	25.2	21.0	22.3	
Two-vessel disease	20.5	23.8	23.2	21.6	
Three-vessel disease	25.1	25.2	32.2	35.1	
Prior CVD, %					
AMI	37.0	42.1	40.5	41.4	0.08
PAD	6.0	8.9	9.6	11.9	<0.001
PCI	18.4	18.4	18.2	21.2	0.25
CABG	9.9	11.1	11.8	13.4	0.09
TMAO precursors (plasma)					
Choline, µmol/L	9.2 (2.1)	9.8 (2.4)	10.4 (2.6)	10.8 (3.2)	<0.001
Betaine, µmol/L	39.1 (13.4)	40.3 (12.9)	41.7 (14.7)	42.5 (13.2)	<0.001
Gamma-butyrobetaine, µmol/L	0.97 (0.23)	1.02 (0.23)	1.07 (0.25)	1.14 (0.31)	<0.001
Carnitine, µmol/L	38.4 (7.4)	39.3 (7.6)	39.6 (7.7)	39.9 (8.2)	<0.001
TML, µmol/L	0.62 (0.25)	0.68 (0.27)	0.76 (0.32)	1.04 (0.73)	<0.001
Hordaland Health Study cohort (n = 6393)					
	Quartile 1 (<3.1)	Quartile 2 (3.1–4.7)	Quartile 3 (4.7–8.3)	Quartile 4 (>8.3)	<i>P</i> <sub>trend</sub>
Age, years	52 (10)	58 (12)	62 (12)	63 (12)	<0.001
Female sex, %	63.1	57.9	53.4	47.4	<0.001
BMI, kg/m <sup>2</sup>	25 (4)	26 (4)	26 (4)	26 (4)	<0.001
Hypertension, %	9.0	14.9	22.4	26.2	<0.001
Diabetes mellitus, %	1.1	2.5	4.5	6.3	<0.001
Current smoking, %	33.6	29	21.5	17.4	<0.001
eGFR, ml/min per 1.73m <sup>2</sup>	77 (11)	72 (12)	69 (13)	66 (13)	<0.001

(Continued)

Table 1. (Continued)

Hordaland Health Study cohort (n = 6393)					
	Quartile 1 (<3.1)	Quartile 2 (3.1–4.7)	Quartile 3 (4.7–8.3)	Quartile 4 (>8.3)	P <sub>trend</sub>
Total cholesterol, mmol/L	5.8 (1.0)	6.0 (1.1)	6.0 (1.1)	6.0 (1.1)	<0.001
Plasma TML, $\mu$ mol/L	0.51 (0.13)	0.55 (0.16)	0.60 (0.17)	0.81 (0.48)	<0.001

Note: Continuous variables are presented as means (standard deviation) and categorical variables are reported as percentages.

Abbreviations: AMI, acute myocardial infarction; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CRP, C-reactive protein; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; TMAO, trimethylamine N-oxide; TML, trimethyllysine; WECAC, Western Norway Coronary Angiography Cohort.

Table 2. Risk association between plasma trimethylamine N-oxide and mortality in patients with suspected coronary heart disease (Western Norway Coronary Angiography Cohort, n = 4132)

Plasma TMAO	Unadjusted		Model 1 <sup>a</sup>		Model 2 <sup>b</sup>	
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
All-cause mortality						
Quartiles						
Q1	Reference		Reference		Reference	
Q2	1.33 (1.07–1.65)	0.01	1.05 (0.84–1.30)	0.68	0.98 (0.79–1.22)	0.86
Q3	1.82 (1.48–2.23)	<0.001	1.21 (0.99–1.49)	0.07	1.08 (0.87–1.33)	0.49
Q4	2.29 (1.88–2.79)	<0.001	1.32 (1.08–1.62)	0.01	1.07 (0.86–1.32)	0.56
Trend	1.32 (1.24–1.40)	<0.001	1.10 (1.04–1.18)	0.02	1.03 (0.96–1.10)	0.39
Per one SD <sup>c</sup>	1.34 (1.26–1.42)	<0.001	1.14 (1.07–1.22)	<0.001	1.04 (0.97–1.12)	0.28
CV mortality						
Quartiles						
Q1	Reference		Reference		Reference	
Q2	1.59 (1.13–2.23)	0.007	1.24 (0.88–1.74)	0.22	1.15 (0.82–1.61)	0.42
Q3	2.41 (1.76–3.31)	<0.001	1.57 (1.14–2.17)	0.005	1.36 (0.98–1.88)	0.06
Q4	2.73 (2.00–3.72)	<0.001	1.52 (1.11–2.09)	0.01	1.16 (0.83–1.62)	0.38
Trend	1.38 (1.26–1.51)	<0.001	1.14 (1.04–1.26)	0.005	1.05 (0.95–1.15)	0.38
Per one SD <sup>c</sup>	1.40 (1.28–1.53)	<0.001	1.19 (1.08–1.31)	0.001	1.06 (0.95–1.18)	0.28
Non-CV mortality						
Quartiles						
Q1	Reference		Reference		Reference	
Q2	1.18 (0.89–1.56)	0.26	0.93 (0.70–1.24)	0.63	0.88 (0.66–1.17)	0.38
Q3	1.45 (1.11–1.90)	0.07	0.99 (0.75–1.30)	0.92	0.90 (0.68–1.19)	0.46
Q4	2.02 (1.57–2.61)	<0.001	1.20 (0.92–1.56)	0.18	1.02 (0.77–1.34)	0.90
Trend	1.27 (1.17–1.38)	<0.001	1.07 (0.99–1.17)	0.09	1.02 (0.93–1.11)	0.70
Per one SD <sup>c</sup>	1.29 (1.18–1.40)	<0.001	1.10 (1.00–1.20)	0.04	1.03 (0.93–1.13)	0.62


Abbreviations: CI, confidence interval; CV, cardiovascular; HR, hazard ratio; Q1, first quartile; Q4, fourth quartile; SD, standard deviation; TMAO, trimethylamine N-oxide.

<sup>a</sup>Adjusted for age and sex.

<sup>b</sup>Adjusted for age and sex, body mass index, diabetes mellitus, smoking, hypertension, estimated glomerular filtration rate, and total cholesterol.

<sup>c</sup>Log transformed.





**Fig. 1** Hazard ratios for mortality per one standard deviation increment of log-transformed trimethylamine N-oxide. Adjusted for age, sex, body mass index, diabetes mellitus, smoking, hypertension, estimated glomerular filtration rate, and total cholesterol.

risk associations of TMAO with mortality in Model 2 without inclusion of eGFR as a covariate. In this simplified model, the HRs per one-SD increment of log-transformed TMAO were 1.12 (1.05–1.20), 1.15 (1.04–1.27), and 1.09 (1.00–1.20) for all-cause, CV, and non-CV mortality, respectively.

## Discussion

### Principal findings

In two large separate cohorts of patients with suspected coronary heart disease (CHD) or community-based adults, plasma TMAO was not predictive of long-term (~10 years) all-cause, CV, or non-CV mortality. These findings were consistent in subgroups of patients with angiographically verified CAD and subjects with reduced LVEF.

### TMAO and clinical outcomes

In recent meta-analyses—which primarily include high-risk patient populations with established CV disease (CVD) or chronic kidney disease—elevated TMAO was related to the risk of CV events [7] and mortality [18]. In a community-based case-control study of older adults [19], TMAO was associated with incident atherosclerotic CVD. On the other hand, no relationship of TMAO with CV events was observed among subjects free of CVD in a case-cohort study from the PREDIMED trial during a 4.8-year follow-up [20]. Similar null associations were recently reported in diabetic patients [21, 22]. Observational studies among patients with established CVD also show inconsistencies [5]. For instance, prospective studies on CV patients reported no independent associations of TMAO with acute myocardial infarction [23] or incident CVD events [24].

Consistent across the primary and secondary prevention cohorts of the present study, TMAO was

not predictive of all-cause, CV, or non-CV mortality after multivariable adjustments, suggesting that TMAO does not improve risk prediction beyond the established risk factors. In contrast to a recent meta-analysis [25] and a multicenter European study [26], we found similar results in patients with verified CAD and patients with reduced LVEF. However, only a small subset of WECAC patients had LVEF  $\leq 40\%$ , necessitating cautious interpretation of this subgroup analysis.

Geographic, ethnic, and dietary variations [5, 27, 28]—as well as differences in follow-up, endpoint definitions, and model adjustments—may underlie discrepancies across studies evaluating TMAO as a marker of adverse prognosis. As evident for other emerging biomarkers [29], the magnitude and validity of the reported risk associations may also be subject to publication bias [18]. Of note, the size of the population sample of the present study was higher than one fourth of the largest meta-analysis on TMAO and mortality published to date [8].

### TMAO and renal function

TMAO is primarily eliminated unchanged in urine and is markedly elevated in patients with chronic kidney disease [30]. Accordingly, we observed negative associations of plasma TMAO with eGFR in both cohorts. Based on limited data from animal models [30–32] showing renal damage from elevated TMAO concentrations, a potential bidirectional relationship of plasma TMAO and kidney disease has been hypothesized. In contrast, a recent Mendelian randomization analysis found no association of genetically elevated TMAO with renal dysfunction or cardiometabolic health [33].

In line with some [34, 35]—but not all [36]—previous investigations, there was a trend towards a stronger relationship of TMAO with mortality

**Table 3.** Risk associations between plasma trimethylamine N-oxide and risk of mortality in community-based subjects (Hordaland Health Study cohort,  $n = 6393$ )

Plasma TMAO	Unadjusted		Model 1 <sup>a</sup>		Model 2 <sup>b</sup>	
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
All-cause mortality						
Quartiles						
Q1	Reference		Reference		Reference	
Q2	1.75 (1.39–2.21)	<0.001	1.01 (0.80–1.28)	0.95	1.03 (0.82–1.31)	0.80
Q3	2.44 (1.95–3.04)	<0.001	1.00 (0.80–1.25)	0.99	1.03 (0.82–1.29)	0.80
Q4	3.07 (2.48–3.80)	<0.001	1.09 (0.88–1.37)	0.43	1.11 (0.88–1.40)	0.38
Trend	1.41 (1.33–1.50)	<0.001	1.03 (0.97–1.10)	0.34	1.03 (0.97–1.11)	0.34
Per one SD <sup>c</sup>	1.35 (1.27–1.42)	<0.001	1.04 (0.97–1.11)	0.29	1.03 (0.96–1.10)	0.49
CV mortality						
Quartiles						
Q1	Reference		Reference		Reference	
Q2	1.55 (1.00–2.38)	0.05	0.81 (0.52–1.25)	0.33	0.79 (0.51–1.23)	0.30
Q3	2.62 (1.76–3.90)	<0.001	0.93 (0.62–1.39)	0.73	0.87 (0.58–1.31)	0.51
Q4	3.75 (2.56–5.49)	<0.001	1.13 (0.77–1.70)	0.54	0.97 (0.65–1.46)	0.88
Trend	1.56 (1.39–1.74)	<0.001	1.09 (0.97–1.12)	0.15	1.03 (0.91–1.17)	0.65
Per one SD <sup>c</sup>	1.43 (1.30–1.57)	<0.001	1.08 (0.97–1.21)	0.18	1.01 (0.89–1.13)	0.94
Non-CV mortality						
Quartiles						
Q1	Reference		Reference		Reference	
Q2	1.84 (1.40–2.43)	<0.001	1.11 (0.84–1.46)	0.48	1.15 (0.87–1.52)	0.32
Q3	2.36 (1.81–3.07)	<0.001	1.03 (0.78–1.35)	0.83	1.11 (0.84–1.46)	0.46
Q4	2.77 (2.14–3.60)	<0.001	1.07 (0.82–1.40)	0.64	1.17 (0.88–1.54)	0.28
Trend	1.35 (1.26–1.46)	<0.001	1.01 (0.93–1.09)	0.87	1.04 (0.95–1.13)	0.41
Per one SD <sup>c</sup>	1.31 (1.22–1.40)	<0.001	1.01 (0.94–1.10)	0.73	1.03 (0.95–1.12)	0.46

Abbreviations: CI, confidence interval; CV, cardiovascular; HR, hazard ratio; Q1, first quartile; Q4, fourth quartile; SD, standard deviation; TMAO, trimethylamine N-oxide.

<sup>a</sup>Adjusted for age and sex.

<sup>b</sup>Adjusted for age, sex, body mass index, diabetes mellitus, smoking, hypertension, estimated glomerular filtration rate, and total cholesterol.

<sup>c</sup>Log transformed.

in patients with lower eGFR. However, the differences were numerically small and not statistically significant across the cohorts. Of note, TMAO was predictive of mortality in multivariable models in WECAC after exclusion of eGFR as a covariate. Indeed, impaired renal function has been suggested as a major confounder in analyses of TMAO-related adverse outcomes in patients with established CHD [24, 37], and our results clearly support that eGFR attenuates the associations of TMAO with adverse outcomes.

#### TMAO and non-CV mortality

Recent observational data have suggested relationships of TMAO with leading causes of non-CV mor-

tality, such as dementia [38, 39] and carcinogenesis [40]. However, a potential causal role of TMAO is largely unexplored. To our knowledge, this is the first study to assess associations of plasma TMAO with non-CV mortality, which was the main contributor to all-cause mortality both in the general population sample and for patients with CHD. As observed for CV mortality, TMAO had no predictive value for non-CV mortality in either study cohort.

#### Strengths and limitations

Major strengths of this prospective study include the large number of participants, the long-term follow-up and the replication of results in two separate patient populations with different base-

line risks. Further, endpoint data were obtained from a national registry with almost 100 percent coverage. Approximately 45 percent of the total study population were women, providing adequate gender representation. Another strength is that samples were analyzed simultaneously at the same laboratory by technicians blinded to clinical data, and TMAO and precursors were measured by a targeted LC-MS/MS method that included authentic labelled internal standards for all metabolites, thereby providing high precision and accuracy and no assay interference [41].

We are aware of several limitations. First, we included only single baseline TMAO measurements in the analyses, which may result in underestimation of true risk relationships by regression dilution bias, due to low within-subject reproducibility of TMAO [42]. Second, study participants were mainly Caucasian subjects from Western Norway, potentially limiting generalizability to other populations. Third, the majority of participants provided nonfasting blood samples. Fourth, inherent to any observational design, inferences of causation cannot be drawn, although the clinical utility of a biomarker for risk stratification does not necessarily depend on causal relationships [43].

## Conclusions

In this prospective study of more than 10,000 subjects with or without established CHD, circulating TMAO did not predict long-term risk of all-cause, CV, or non-CV mortality. Our results do not support the use of TMAO for patient risk stratification in primary or secondary prevention.

## Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

## Conflicts of interest

The authors declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.

## Author contributions

Espen Ø. Bjørnstad: Conceptualization; Formal analysis; Methodology; Visualization; Writing - original draft; Writing - review and editing. Indu Dhar: Data curation; Formal analysis; Methodol-

ogy; Visualization; Writing - original draft; Writing - review and editing. Gard F. T. Svingen: Investigation; Methodology; Writing - review and editing. Eva R. Pedersen: Investigation; Methodology; Writing - review and editing. Stein Ørn: Investigation; Supervision; Writing - review and editing. Mads M. Svenningsson: Investigation; Writing - review and editing. Grethe S. Tell: Investigation; Methodology; Project administration; Writing - review and editing. Per M. Ueland: Investigation; Methodology; Project administration; Writing - review and editing. Gerhard Sulo: Formal analysis; Methodology; Writing - review and editing. Reijo Laaksonen: Investigation; Methodology; Writing - review and editing. Ottar Nygård: Conceptualization; Formal analysis; Investigation; Methodology; Project administration; Supervision; Writing - review and editing.

## References

- 1 Tang WHW, Bäckhed F, Landmesser U, Hazen SL. Intestinal microbiota in cardiovascular health and disease: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019;**73**(16):2089–105.
- 2 Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. *Circ Res*. 2020;**127**(4):553–70.
- 3 Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. *Gut*. 2021;**70**(6):1174–82.
- 4 Al-Waiz M, Mitchell SC, Idle JR, Smith RL. The metabolism of 14C-labelled trimethylamine and its *N*-oxide in man. *Xenobiotica*. 1987;**17**(5):551–8.
- 5 Zeisel SH, Warrier M. Trimethylamine *N*-oxide, the microbiome, and heart and kidney disease. *Annu Rev Nutr*. 2017;**37**:157–81.
- 6 Kühn T, Rohrmann S, Sookthai D, Johnson T, Katzke V, Kaaks R, et al. Intra-individual variation of plasma trimethylamine-*N*-oxide (TMAO), betaine and choline over 1 year. *Clin Chem Lab Med*. 2017;**55**(2):261–8.
- 7 Schiattarella GG, Sannino A, Toscano E, Giugliano G, Gargiulo G, Franzese A, et al. Gut microbe-generated metabolite trimethylamine-*N*-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. *Eur Heart J*. 2017;**38**(39):2948–56.
- 8 Li D, Lu Y, Yuan S, Cai X, He Y, Chen J, et al. Gut microbiota-derived metabolite trimethylamine-*N*-oxide and multiple health outcomes: an umbrella review and updated meta-analysis. *Am J Clin Nutr*. 2022;**116**:230–43.
- 9 Meyer KA. Population studies of TMAO and its precursors may help elucidate mechanisms. *Am J Clin Nutr*. 2020;**111**(6):1115–6.
- 10 Svingen GF, Ueland PM, Pedersen EK, Schartum-Hansen H, Seifert R, Ebbing M, et al. Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris. *Arterioscler Thromb Vasc Biol*. 2013;**33**(8):2041–8.
- 11 Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after



- coronary angiography: a randomized controlled trial. *JAMA*. 2008;**300**(7):795–804.
- 12 Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. *J Nutr*. 2006;**136**(6 Suppl):1731s–40s.
  - 13 Bjørnstad EØ, Dhar I, Svingen GFT, Pedersen ER, Svenningsson MM, Tell GS, et al. Trimethyllysine predicts all-cause and cardiovascular mortality in community-dwelling adults and patients with coronary heart disease. *Eur Heart J Open*. 2021;**1**(1):oeab007.
  - 14 Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;**150**(9):604–12.
  - 15 Dhar I, Svingen GFT, Olsen T, Lysne V, Bjørnstad E, Ueland PM, et al.  $\beta$ -blocker use and risk of all-cause mortality in patients with coronary heart disease: effect modification by serum vitamin A. *Eur J Prev Cardiol*. 2022;**28**(17):1897–902.
  - 16 Midttun Ø, Kvalheim G, Ueland PM. High-throughput, low-volume, multianalyte quantification of plasma metabolites related to one-carbon metabolism using HPLC-MS/MS. *Anal Bioanal Chem*. 2013;**405**(6):2009–17.
  - 17 Pedersen AG, Ellingsen CL. Data quality in the Causes of Death Registry. *Tidsskr Nor Laegeforen*. 2015;**135**(8):768–70.
  - 18 Farhangi MA. Gut microbiota-dependent trimethylamine *N*-oxide and all-cause mortality: findings from an updated systematic review and meta-analysis. *Nutrition*. 2020;**78**:110856.
  - 19 Tang WHW, Li XS, Wu Y, Wang Z, Khaw KT, Wareham NJ, et al. Plasma trimethylamine *N*-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study. *Am Heart J*. 2021;**236**:80–6.
  - 20 Guasch-Ferré M, Hu FB, Ruiz-Canela M, Bulló M, Toledo E, Wang DD, et al. Plasma metabolites from choline pathway and risk of cardiovascular disease in the PREDIMED (Prevention With Mediterranean Diet) Study. *J Am Heart Assoc*. 2017;**6**(11):e006524.
  - 21 Cardona A, O'Brien A, Bernier MC, Somogyi A, Wysocki VH, Smart S, et al. Trimethylamine *N*-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis. *BMJ Open Diabetes Res Care*. 2019;**7**(1):e000718.
  - 22 Winther SA, Øllgaard JC, Hansen TW, von Scholten BJ, Reinhard H, Ahluwalia TS, et al. Plasma trimethylamine *N*-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. *PLoS One*. 2021;**16**(3):e0244402.
  - 23 Bjørnstad E, Olset H, Dhar I, Løland K, Pedersen EKR, Svingen GFT, et al. Circulating trimethyllysine and risk of acute myocardial infarction in patients with suspected stable coronary heart disease. *J Intern Med*. 2020;**288**(4):446–56.
  - 24 Mueller DM, Allenspach M, Othman A, Saely CH, Muendlein A, Vonbank A, et al. Plasma levels of trimethylamine-*N*-oxide are confounded by impaired kidney function and poor metabolic control. *Atherosclerosis*. 2015;**243**(2):638–44.
  - 25 Yao ME, Liao PD, Zhao XJ, Wang L. Trimethylamine-*N*-oxide has prognostic value in coronary heart disease: a meta-analysis and dose-response analysis. *BMC Cardiovasc Disord*. 2020;**20**(1):7.
  - 26 Suzuki T, Yazaki Y, Voors AA, Jones DJL, Chan DCS, Anker SD, et al. Association with outcomes and response to treatment of trimethylamine *N*-oxide in heart failure: results from BIOSTAT-CHF. *Eur J Heart Fail*. 2019;**21**(7):877–86.
  - 27 Yazaki Y, Salzano A, Nelson CP, Voors AA, Anker SD, Cleland JG, et al. Geographical location affects the levels and association of trimethylamine *N*-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis. *Eur J Heart Fail*. 2019;**21**(10):1291–4.
  - 28 Yazaki Y, Aizawa K, Israr MZ, Negishi K, Salzano A, Saitoh Y, et al. Ethnic differences in association of outcomes with trimethylamine *N*-oxide in acute heart failure patients. *ESC Heart Fail*. 2020;**7**(5):2373–8.
  - 29 Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JP. Bias in associations of emerging biomarkers with cardiovascular disease. *JAMA Intern Med*. 2013;**173**(8):664–71.
  - 30 Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatista-Boyle B, et al. Gut microbiota-dependent trimethylamine *N*-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. *Circ Res*. 2015;**116**(3):448–55.
  - 31 Gupta N, Buffa JA, Roberts AB, Sangwan N, Skye SM, Li L, et al. Targeted inhibition of gut microbial trimethylamine *N*-oxide production reduces renal tubulointerstitial fibrosis and functional impairment in a murine model of chronic kidney disease. *Arterioscler Thromb Vasc Biol*. 2020;**40**(5):1239–55.
  - 32 Sun G, Yin Z, Liu N, Bian X, Yu R, Su X, et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity. *Biochem Biophys Res Commun*. 2017;**493**(2):964–70.
  - 33 Jia J, Dou P, Gao M, Kong X, Li C, Liu Z, et al. Assessment of causal direction between gut microbiota-dependent metabolites and cardiometabolic health: a bidirectional mendelian randomization analysis. *Diabetes*. 2019;**68**(9):1747–55.
  - 34 Gruppen EG, Garcia E, Connelly MA, Jeyarajah EJ, Otvos JD, Bakker SJL, et al. TMAO is associated with mortality: impact of modestly impaired renal function. *Sci Rep*. 2017;**7**(1):13781.
  - 35 Lee Y, Nemet I, Wang Z, Lai HTM, de Oliveira Otto MC, Lemaitre RN, et al. Longitudinal plasma measures of trimethylamine *N*-oxide and risk of atherosclerotic cardiovascular disease events in community-based older adults. *J Am Heart Assoc*. 2021;**10**(17):e020646.
  - 36 Gencer B, Li XS, Gurmu Y, Bonaca MP, Morrow DA, Cohen M, et al. Gut microbiota-dependent trimethylamine *N*-oxide and cardiovascular outcomes in patients with prior myocardial infarction: a nested case control study from the PEGASUS-TIMI 54 trial. *J Am Heart Assoc*. 2020;**9**(10):e015331.
  - 37 Rodelo-Haad C, Pendón-Ruiz de Mier MV, Soriano S, Rodríguez M, Santamaria R. Trimethylamine *N*-oxide and coronary heart disease: should we consider the kidney function? *J Am Coll Cardiol*. 2020;**75**(24):3101–2.
  - 38 Cryan JF, O'Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. *Lancet Neurol*. 2020;**19**(2):179–94.
  - 39 Vogt NM, Romano KA, Darst BF, Engelman CD, Johnson SC, Carlsson CM, et al. The gut microbiota-derived metabolite trimethylamine *N*-oxide is elevated in Alzheimer's disease. *Alzheimers Res Ther*. 2018;**10**(1):124.
  - 40 Chan CWH, Law BMH, Waye MMY, Chan JYW, So WKW, Chow KM. Trimethylamine-*N*-oxide as one hypothetical

link for the relationship between intestinal microbiota and cancer—where we are and where shall we go? *J Cancer*. 2019;**10**(23):5874–82.

- 41 Ulvik A, McCann A, Midttun Ø, Meyer K, Godfrey KM, Ueland PM. Quantifying precision loss in targeted metabolomics based on mass spectrometry and nonmatching internal standards. *Anal Chem*. 2021;**93**(21):7616–24.
- 42 Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. *Am J Epidemiol*. 1999;**150**(4):341–53.
- 43 Pletcher MJ, Pignone M. Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. *Circulation*. 2011;**123**(10):1116–24.

*Correspondence:* Espen Ø. Bjørnstad, Department of Cardiology, Stavanger University Hospital, Stavanger, Norway.

Email: espen.bjornestad@gmail.com

### Supporting Information

Additional Supporting Information may be found in the online version of this article:

**Supplemental Table 1:** Risk-associations between plasma trimethylamine *N*-oxide and mortality in patients ( $n = 3095$ ) with angiographically significant coronary artery disease.

**Supplemental Table 2:** Risk-associations between plasma trimethylamine *N*-oxide (log transformed) and mortality according to subgroups. ■